Article
Endocrinology & Metabolism
Sandy Maumus-Robert, Ana Jarne-Munoz, Antoine Pariente, Thomas Duroux, Lise Duranteau, Julien Bezin
Summary: Through an investigation of a large nationwide database, we found no association between statin use and adrenal insufficiency. The risk, if any, seems to be very limited and does not compromise the benefit of statin treatment.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Medicine, General & Internal
William S. Weintraub, Deepak L. Bhatt, Zugui Zhang, Sarahfaye Dolman, William E. Boden, Adam P. Bress, Jordan B. King, Brandon K. Bellows, Gabriel S. Tajeu, Catherine G. Derington, Jonathan Johnson, Katherine Andrade, P. Gabriel Steg, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Jean-Claude Tardif, Christie M. Ballantyne, Paul Kolm
Summary: The study demonstrates the cost-effectiveness of Icosapent ethyl compared with standard care for high-risk patients with hypertriglyceridemia. Treatment with IPE yields more quality-adjusted life-years (QALYs) and better cardiovascular outcomes than standard care both in-trial and over a lifetime projection.
Article
Cardiac & Cardiovascular Systems
Chandini Raina MacIntyre, Abrar Ahmad Chughtai, Arpita Das, Bayzidur Rahman, Aye M. Moa, Chieh H. Gan, Timothy C. Tan
Summary: The study found a significantly higher rate of laboratory-confirmed influenza among statin users who were not vaccinated. However, there was no significant difference in influenza vaccine effectiveness between statin users and non-users after vaccination. Statin users had a significantly higher risk of influenza, suggesting that they should be vaccinated against influenza.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2021)
Article
Health Care Sciences & Services
Lisong Zhang, Jim Lewsey, David A. McAllister
Summary: This article reviews the use of physician's prescribing preference as an instrumental variable (PPP IV) in comparative effectiveness research (CER) and evaluates its performance through simulation studies. The findings suggest that the appropriate use of PPP IV can provide useful guidance, and existing studies have concluded that PPP IV is a valid instrumental variable. Future research should consider methodological issues to improve the validity of findings when using PPP IV.
JOURNAL OF CLINICAL EPIDEMIOLOGY
(2022)
Article
Infectious Diseases
Justine Benevent, Melanie Araujo, Anna-Belle Beau, Diane Sicard, Agnes Sommet, Caroline Hurault-Delarue, Isabelle Lacroix, Christine Damase-Michel
Summary: This study is the first large comparative study assessing the safety of fosfomycin in pregnancy. The results show that first trimester exposure to fosfomycin does not increase the risk of major congenital anomalies.
Article
Cardiac & Cardiovascular Systems
Zanfina Ademi, Richard Ofori-Asenso, Ella Zomer, Alice Owen, Danny Liew
Summary: The study aimed to assess the cost-effectiveness of icosapent ethyl in combination with statin therapy for the prevention of cardiovascular disease in the Australian public healthcare system. Results suggest that the combination therapy may be cost-effective, especially in the secondary preventive setting.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2021)
Article
Medicine, Research & Experimental
Joonsang Yoo, Jimin Jeon, Minyoul Baek, Sun Ok Song, Jinkwon Kim
Summary: This study used a population-based cohort to investigate the relationship between statin treatment and cardiovascular risk in T1D patients. The results showed that statin use was associated with a reduced risk of cardiovascular events, particularly ischemic stroke and myocardial infarction. The risk of cardiovascular events decreased as the cumulative exposure duration of statins increased.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Oncology
Oliver William Scott, Sandar TinTin, Sixten Harborg, Marion J. J. Kuper-Hommel, Ross Lawrenson, J. Mark Elwood
Summary: This study examines the association between the post-diagnostic use of statins and breast cancer outcomes in New Zealand women. The findings suggest that statin use is associated with a decreased risk of breast cancer death, especially in ER+ patients, postmenopausal women, and women with advanced stage disease.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Geriatrics & Gerontology
Siti Z. Suki, Ahmad S. M. Zuhdi, Abqariyah A. Yahya, Nur L. Zaharan
Summary: Octogenarians and beyond have often been neglected in disease research despite being at high non-modifiable disease risk burden and the fastest-growing age group. This study examined the characteristics and in-hospital management of octogenarian patients with acute coronary syndrome (ACS) in a multi-ethnic, middle-income country in Southeast Asia.
Article
Pharmacology & Pharmacy
Sheng-Yu Lee, Liang-Jen Wang, Yao-Hsu Yang, Chih-Wei Hsu
Summary: This study compared the effectiveness of different antidepressants in treating youths with major depressive disorder (MDD). The findings suggest that bupropion may be more effective than fluoxetine in preventing hospitalization and maintaining drug therapy, while mirtazapine users have a higher risk of hospitalization.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE
(2022)
Article
Health Care Sciences & Services
Ippazio Cosimo Antonazzo, Carla Fornari, Sandy Maumus-Robert, Eleonora Cei, Olga Paoletti, Pietro Ferrara, Sara Conti, Paolo Angelo Cortesi, Lorenzo Giovanni Mantovani, Rosa Gini, Giampiero Mazzaglia
Summary: This study explored the impact of COVID-19 lockdowns on the use of antidepressant drugs in the general population. The study found that there was a reduction in the incidence and prevalence of antidepressant drug use during the lockdown periods, followed by an increase after the lockdowns. This suggests that the pandemic has had an impact on people's mental health and may lead to rebound effects between lockdowns.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Enrico Longato, Barbara Di Camillo, Giovanni Sparacino, Lara Tramontan, Angelo Avogaro, Gian Paolo Fadini
Summary: This retrospective study compared cardiovascular outcomes of patients with T2D who received human-based or exendin-based GLP-1RA in routine clinical practice. The results showed better cardiovascular outcomes among patients treated with human-based GLP-1RA than those treated with exendinbased GLP-1RA, providing moderate evidence to guide clinical decision-making.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2021)
Article
Pharmacology & Pharmacy
Ying-Jung Tseng, Yu-Chiang Hung, Chun-En Kuo, Chia-Jung Chung, Chung Y. Hsu, Chih-Hsin Muo, Sheng-Feng Hsu, Wen-Long Hu
Summary: This study is the first to identify the most common conditions for which radix Salvia miltiorrhiza (Danshen; RSM) is used in modern Taiwan, showing its key role in treating gynecological diseases such as menstrual disorders, abnormal bleeding from the female genital tract, and menopausal disorders. RSM is often combined with Yan-Hu-Suo and Jia-Wei-Xiao-Yao-San for clinical use. Further research is needed to determine the optimal dosage, efficacy, and safety of RSM.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Public, Environmental & Occupational Health
Ming-Hsueh Tsai, Tom C. Chan, Meng-Sui Lee, Mei-Shu Lai
Summary: The study found that in a nationwide cohort of patients with psoriasis in Taiwan, compared to retinoids, MTX was associated with a modestly lower risk of cardiovascular events.
CLINICAL EPIDEMIOLOGY
(2021)
Article
Oncology
Johanna Simin, Habiba Khodir, Romina Fornes, Rulla M. Tamimi, Nele Brusselaers
Summary: This Swedish population-based matched cohort study investigated the association between menopausal hormones and the risk of all-cause, cardiovascular, and cancer-specific mortality. The results showed a slight decrease in the odds of all-cause and cancer-related mortality with the use of menopausal hormones, while the association with cardiovascular mortality was inconsistent. Estrogen-only therapy was associated with increased odds of all-cause and cardiovascular mortality among older women who began treatment at a later age.
Article
Cardiac & Cardiovascular Systems
Andre Lamy, John Eikelboom, Wesley Tong, Fei Yuan, Shrikant Bangdiwala, Jackie Bosch, Stuart Connolly, Eva Lonn, Gilles R. Dagenais, Kelley R. H. Branch, Wei-Jhih Wang, Deepak L. Bhatt, Jeff Probstfield, Georg Ertl, Stefan Stoerk, P. Gabriel Steg, Victor Aboyans, Isabelle Durand-Zaleski, Lars Ryden, Salim Yusuf
Summary: The addition of rivaroxaban 2.5 mg BID to aspirin in patients with stable coronary artery disease or peripheral artery disease was found to reduce direct healthcare costs. In Canada, France, and Germany, the combination of rivaroxaban and aspirin was highly cost-effective in terms of lifetime cost-effectiveness.
EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES
(2023)
Article
Economics
Manon Belhassen, Olivier Hanon, Philippe Gabriel Steg, Isabelle Mahe, Melanie Nee, Flore Jacoud, Faustine Dalon, Francois-Emery Cotte, Dominique Guitard-Dehoux, Claire Marant-Micallef, Eric Van Ganse, Nicolas Danchin
Summary: This study compared the costs of healthcare resource use, stroke/systemic thromboembolism, and major bleedings between non-valvular atrial fibrillation patients who initiated apixaban and other oral anticoagulants. The results showed that patients initiating apixaban had lower costs in terms of healthcare resource use and event-related costs compared to other oral anticoagulants. Apixaban may be cost-saving compared to VKAs and cheaper than other DOACs, although the cost differences are limited.
EUROPEAN JOURNAL OF HEALTH ECONOMICS
(2023)
Article
Cardiac & Cardiovascular Systems
Batric Popovic, Gregory Ducrocq, Yedid Elbez, Christoph Bode, Shamir. R. Mehta, Charles Pollack, Manel Sabate, Sunil Rao, Alexander Parkhomenko, Laurent J. Feldman, Neila Sayah, Marc S. Sabatine, Philippe Gabriel Steg
Summary: In patients with non-ST-elevation myocardial infarction (NSTEMI), total occlusion of the culprit coronary artery (OCA) is not uncommon. This study aimed to determine the frequency and clinical impact of OCA at presentation in a large population of patients with NSTEMI who underwent early invasive management. The results showed that patients with OCA had earlier coronary angiography, less involvement of the left anterior descending artery, higher prevalence of angiographic thrombus, higher mortality at 7 days, but similar mortality rates at 6 months.
AMERICAN JOURNAL OF CARDIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Judith S. Hochman, Rebecca Anthopolos, Harmony. R. Reynolds, Sripal Bangalore, Yifan Xu, Sean M. O'Brien, Stavroula Mavromichalis, Michelle Chang, Aira Contreras, Yves Rosenberg, Ruth Kirby, Balram Bhargava, Roxy Senior, Ann Banfield, Shaun G. Goodman, Renato D. Lopes, Radoslaw Pracon, Jose Lopez-Sendon, Aldo Pietro Maggioni, Jonathan D. Newman, Jeffrey S. Berger, Mandeep S. Sidhu, Harvey D. White, Andrea B. Troxel, Robert A. Harrington, William E. Boden, Gregg W. Stone, Daniel B. Mark, John A. Spertus, David J. Maron
Summary: The ISCHEMIA trial compared the outcomes of initial invasive strategy versus initial conservative strategy in patients with chronic coronary disease and moderate or severe ischemia. The trial found no major difference in most outcomes, but there was lower risk of cardiovascular mortality and higher risk of noncardiovascular mortality with the invasive strategy.
Editorial Material
Cardiac & Cardiovascular Systems
Philippe Gabriel Steg, John Kikoine
Article
Cardiac & Cardiovascular Systems
Francesco Costa, Claudio Montalto, Mattia Branca, Sung-Jin Hong, Hirotoshi Watanabe, Anna Franzone, Pascal Vranckx, Joo-Yong Hahn, Hyeon-Cheol Gwon, Fausto Feres, Yangsoo Jang, Giuseppe De Luca, Elvin Kedhi, Davide Cao, Philippe Gabriel Steg, Deepak L. Bhatt, Gregg W. Stone, Antonio Micari, Stephan Windecker, Takeshi Kimura, Myeong-Ki Hong, Roxana Mehran, Marco Valgimigli
Summary: The study evaluated the impact of an abbreviated dual antiplatelet therapy (DAPT) regimen in high bleeding risk patients after percutaneous coronary intervention (PCI), using existing evidence. It found that a shorter DAPT duration (1-3 months) reduced bleeding and cardiovascular mortality without increasing ischemic events in these patients.
EUROPEAN HEART JOURNAL
(2023)
Article
Pharmacology & Pharmacy
William A. E. Parker, Dominick J. Angiolillo, Fabiana Rollini, Francesco Franchi, Marc P. Bonaca, Deepak L. Bhatt, Ph. Gabriel Steg, Rachel C. Orme, Mark R. Thomas, Heather M. Judge, Marc S. Sabatine, Robert F. Storey
Summary: This study investigated the influence of body mass on the response to ticagrelor treatment in patients with chronic coronary syndromes. The results showed that body weight was positively correlated with P2Y12 reactivity units before drug administration, but not after. The dosage of 60 mg ticagrelor was significantly correlated with body mass index. However, body mass did not affect the chance of high platelet reactivity. Overall, the currently-used regimens are adequate across different body weights and body mass index in this patient population.
VASCULAR PHARMACOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Brian Olshansky, Deepak L. L. Bhatt, Michael Miller, Ph. Gabriel Steg, Eliot A. A. Brinton, Terry A. A. Jacobson, Steven B. B. Ketchum, Ralph T. T. Doyle Jr, Rebecca A. A. Juliano, Lixia Jiao, Peter R. R. Kowey, James A. A. Reiffel, Jean-Claude Tardif, Christie M. M. Ballantyne, Mina K. K. Chung
Summary: In the REDUCE-IT study, icosapent ethyl (IPE) reduced cardiovascular events but was associated with increased atrial fibrillation/atrial flutter (AF) hospitalization. The study analyzed the relationships between IPE and outcomes in patients with or without prior AF and with or without in-study AF hospitalization. Overall, in-study AF hospitalization rates were higher in patients with prior AF, especially in those randomized to IPE. Serious bleeding rates also trended higher in these patients. However, patients with prior AF or in-study AF hospitalization showed consistent risk reductions in cardiovascular events with IPE.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Maroua Mimouni, Julie Bulsei, Meryl Darlington, Candice Estellat, Francois Rouzet, Fabien Hyafil, Isabelle Durand-Zaleski
Summary: This study evaluated the cost-effectiveness of Rb-PET-MPI compared to Tc-SPECT-MPI for detecting myocardial ischemia, and the results showed that Rb-PET-MPI was a cost-saving and outcome-improving option for patients with PTP > 15%.
Editorial Material
Cardiac & Cardiovascular Systems
Christopher W. Baugh, Yonathan Freund, Philippe Gabriel Steg, Richard Body, David J. Maron, Maame Yaa A. B. Yiadom
Summary: Emergency department (ED) crowding is a global problem caused by hospital capacity and other health system challenges. Patients with cardiovascular emergencies are particularly vulnerable due to the crowding, which may lead to avoidance of the ED, premature departure, or delays in receiving care. This paper discusses the causes of crowding, its impact on cardiovascular emergencies, and potential solutions.
EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE
(2023)
Article
Geriatrics & Gerontology
Sandy Maumus-Robert, Ana Jarne-Munoz, Marie Tournier, Bernard Begaud, Antoine Pariente
Summary: This study aimed to characterize trajectories of benzodiazepine use in older adults and identify risk factors. A cohort of 5080 adults aged 65 and older who initiated benzodiazepine use in 2007 was followed for up to 8 years using the French Health Insurance database. About one-third of older adults had non-guideline-concordant trajectories, which were associated with factors such as polypharmacy, long-term disease, and hospitalization.
Article
Cardiac & Cardiovascular Systems
Alexandre Gautier, Fabien Picard, Gregory Ducrocq, Yedid Elbez, Kim M. Fox, Roberto Ferrari, Ian Ford, Jean-Claude Tardif, Michal Tendera, Philippe Gabriel Steg
Summary: This study found that new-onset atrial fibrillation (NOAF) is common among patients with chronic coronary syndromes (CCS) and is associated with increased risk of cardiovascular adverse events. Age, body mass index, glomerular filtration rate, ethnicity, alcohol intake, and left ventricular ejection fraction were identified as predictors of NOAF. The study suggests that more intensive preventive measures and systematic screening for atrial fibrillation should be considered in this patient population.
EUROPEAN HEART JOURNAL
(2023)
Article
Pharmacology & Pharmacy
Francesco Salvo, Joelle Micallef, Amir Lahouegue, Laurent Chouchana, Louis Letinier, Jean-Luc Faillie, Antoine Pariente
Summary: Artificial intelligence (AI) and intelligent automation (IA) tools provide new opportunities for pharmacovigilance (PV) activities, but their contribution needs to be tailored to preserve and strengthen medical and pharmacological expertise. AI and IA tools will assist in various PV tasks, particularly for low added value tasks such as initial quality check and search for duplicates.
EXPERT OPINION ON DRUG SAFETY
(2023)
Letter
Cardiac & Cardiovascular Systems
Shaun G. Goodman, Philippe Gabriel Steg, Yann Poulouin, Deepak L. Bhatt, Vera A. Bittner, Rafael Diaz, Genevieve Garon, Robert A. Harrington, J. Wouter Jukema, Garen Manvelian, Wanda Stipek, Michael Szarek, Harvey D. White, Gregory G. Schwartz
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2023)
Article
Cardiac & Cardiovascular Systems
Amandine Gouverneur, Paola Sanchez-Pena, Gwenaelle Veyrac, Joe-Elie Salem, Bernard Begaud, Julien Bezin
Summary: This study investigated the neurocognitive adverse events associated with the use of PCSK9 inhibitors and found a signal of neurocognitive disorders associated with these inhibitors.
CARDIOVASCULAR DRUGS AND THERAPY
(2023)
